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IgA nephropathy (IgAN) was described
histologically for the first time in 1968 by
Berger andHinglais as les de´poˆts intercap-
illaires d’IgA-IgG (intercapillary deposits
of IgA-IgG).1 Over the ensuing decades,
this renal disease has been recognized as
the most common primary glomerulo-
nephritis and has been shown to arise
from a systemic process wherein the kid-
neys are damaged as innocent bystand-
ers. The latter point is best illustrated by
the experience with renal transplanta-
tion. IgAN frequently recurs in allo-
grafts; in contrast, kidneys from donors
with subclinical IgAN are clear of IgA de-
posits shortly after transplantation into
recipients with non-IgAN renal dis-
eases.2 The glomerular IgA eluted from
tissue specimens from patients with
IgAN is exclusively of the IgA1 sub-
class, predominantly in the polymeric
form, and, most importantly, glycosy-
lated aberrantly. Specifically, this aber-
rant IgA1 exhibits galactose deficiency
in the O-linked glycans in the hinge re-
gion of the heavy chain. Blood levels of a
similarly aberrantly glycosylated IgA1
are higher in patients with IgAN than in
healthy controls or patients with other
kidney diseases. However, as we discuss
here, a high circulating load of galactose-
deficient IgA1 alone does not induce the
renal injury. Rather, several sequential
processes or hits are necessary for the
clinical expression of IgAN.
PATHOGENESIS OF IgAN
Fourprocesses come together to induce re-
nal injury that culminates in IgAN: aber-
rant glycosylation of IgA1, synthesis of
antibodies directed against galactose-defi-
cient IgA1, binding of the galactose-defi-
cient IgA1 by the anti-glycan/glycopeptide
antibodies to form immune complexes,
and accumulation of these complexes in
the glomerularmesangiumto initiate renal
injury. We recently performed a genome-
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ABSTRACT
Here we discuss recent advances in understanding the biochemical, immunologic,
and genetic pathogenesis of IgA nephropathy, the most common primary glomer-
ulonephritis. Current data indicate that at least four processes contribute to
development of IgA nephropathy. Patients with IgA nephropathy often have a
genetically determined increase in circulating levels of IgA1 with galactose-defi-
cient O-glycans in the hinge-region (Hit 1). This glycosylation aberrancy is, how-
ever, not sufficient to induce renal injury. Synthesis and binding of antibodies
directed against galactose-deficient IgA1 are required for formation of immune
complexes that accumulate in the glomerular mesangium (Hits 2 and 3). These
immune complexes activate mesangial cells, inducing proliferation and secretion of
extracellular matrix, cytokines, and chemokines, which result in renal injury (Hit 4).
Recent genome-wide association studies identify five distinct susceptibility loci—in the
MHC on chromosome 6p21, the complement factor H locus on chromosome 1q32,
and in a cluster of genes on chromosome 22q22—that potentially influence these
processes and contain candidate mediators of disease. The significant variation in
prevalence of risk alleles among different populations may also explain some of the
sizable geographic variation in disease prevalence. Elucidation of the pathogenesis of
IgA nephropathy provides an opportunity to develop disease-specific therapies.
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wide association study (GWAS) that iden-
tified five susceptibility loci for IgAN and
provided molecular candidates for these
processes.3
Hit 1: Hereditary Increase in
Galactose-Deficient Circulating
IgA1
As is the case for other immunoglobu-
lins, IgA1 is glycosylated. An altered
pattern of its glycosylation has been
recognized as a potentially pathogenic
abnormality in IgAN for nearly 20
years.4 The key feature is the deficiency
of galactose in the hinge region of the
IgA1 heavy chains. The hinge region of
IgA1 extends by 13 amino acids longer
than the hinge region of IgA2 and is
found only in humans and higher pri-
mates (Figure 1A).5 It can carry up to
six relatively short and simple sugar
chains, called O-linked glycans, each
attached by glycosidic linkage to an ox-
ygen atom of a serine or threonine.
These glycans are synthesized in stepwise
fashion and include up to six different
forms (Figure 1B). Patients with IgAN
have increased circulating levels of IgA1
with abbreviated glycans composed of N-
acetylgalactosamine (GalNAc), with or
without sialic acid, that are devoid of a ga-
lactose moiety, as in Figure 1B structures I
and II. A GalNAc-specific lectin, Helix
aspersa agglutinin, is frequently used in
an ELISA to measure the amount of ga-
lactose-deficient IgA1 (IgA1 with
hinge-region O-glycan structures I and
II in Figure 1B) after treatment of the
IgA1 with neuraminidase to remove
terminal sialic acid.6 Recent high-
resolution mass spectrometry studies
demonstrate significant heterogeneity
in the composition and attachment
sites of these glycans.7–12 Determina-
tion of the precise structural abnor-
mality in IgAN is complicated by the
multiplicity of O-glycosylation sites
and combinatorial possibilities of gly-
can variants. However, examination of
IgA1-producing cells shows that aber-
rant O-glycosylation in IgAN is driven
by combined abnormalities in expres-
sion or activity of the glycosyltrans-
ferases involved in the sequential post-
translational modification of IgA1
(Figure 1), implicating complex regu-
latory defects.13
Inpatientswith IgAN, thepredominant
sites where the cells secreting galactose-de-
ficient IgA1 originate from and reside re-
main uncertain. Circulatory IgA1 is pro-
ducedmainly in thebonemarrow,whereas
aberrantly glycosylated IgA1 may be syn-
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Figure 1. Human IgA1: hinge-region amino acid sequence (A) and possible glycan
variants (B). (A) IgA1 contains up to six O-glycans per hinge region: five major sites are
shown (in orange or magenta) and the sixth site is Thr233.9 Novel approaches using
IgA-specific bacterial proteases and lectin binding, and, more recently, high-resolu-
tion mass spectrometry with electron capture and electron transfer dissociation, have
been used to determine O-glycan heterogeneity, the sites of glycosylation, and the
microheterogeneity at the individual sites.6,7,9,45,46 The model of intact IgA1 was
generated from published crystal and solution structures of IgA1.47,48 N- and O-
glycans were modeled using the GlyProt server and related databases (http://www.
glycosciences.de), based on observed IgA1 glycoforms.9,49 For clarity, the O-glycans
are shown with transparent spheres for each atom, and are colored orange for
GalNAc-galactose residues and magenta for GalNAc; the illustrated O-glycan distri-
bution was taken from a study by Takahashi et al.9 (B) The variants of O-glycans on
circulatory IgA1. Galactose-deficient glycans present in elevated amounts in patients
with IgAN are represented by structures I and II in magenta.6,19 Galactosylated
variants are in orange as structures III to VI. The largest O-glycan on circulatory IgA1
is a GalNAc-galactose with two sialic acids, i.e., tetrasaccharide, structure VI. IgA1
with GalNAc and sialylated GalNAc (structures I and II in magenta) is present at
elevated serum levels in patients with IgAN due to the changes in expression and
activity of specific glycosyltransferases, ST6GalNAcII, and C1GalT1.50 The stability of
C1GalT1 during translation is controlled by Cosmc, a foldase.51 Structure I is gener-
ated by a GalNAc-transferase52; structure II, by ST6GalNAcII53; structure III, from
structure I by C1GalT154; and structures IV to VI, by sialyltransferases. Symbols:
rectangle, GalNAc; circle, galactose; diamond, sialic acid.
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thesized inresponse toamucosal infection,
and thus abnormalities in the mucosal re-
sponse to commonmicrobial or food anti-
gens may be involved in production of ga-
lactose-deficient IgA1.14 For example,
blood levels of galactose-deficient IgA1 di-
rected against mucosal pathogens are in-
creased in patients with IgAN compared
with those of healthy controls.14 This pro-
cess may include dysregulated innate im-
mune responses through Toll-like recep-
tors.15
Serum levels of galactose-deficient IgA1
are above the 90th percentile for healthy
controls in as many as 70 to 80% of IgAN
patients.6 Furthermore, 40 to 50% of first-
degree relatives of IgAN patients have ele-
vated levels comparable to that of patients,
demonstrating significant heritability of
this trait.16,17 The heritability of galactose-
deficient IgA1 is observed in diverse racial
groups and is not explained by variation in
serum IgA levels, suggesting that distinct
genetic mechanisms influence IgA1 glyco-
sylation and production. These data also
indicate that aberrant IgA1 glycosylation
precedes clinicallyovertdisease andconsti-
tutes an inherited risk factor for the devel-
opment of IgAN.Moreover, because most
persons with elevated levels of galactose-
deficient IgA1 do not exhibit clinical signs
of renal injury, this hereditary defect is in-
sufficient to cause IgAN, implicating addi-
tional pathogenic hits as described in this
article.16
GWAS data have identified a major
locus on chromosome 22q12.2 influenc-
ing susceptibility to IgAN.3 This locus is
also associated with variation in serum
IgA levels and has been previously asso-
ciated with risk of inflammatory bowel
disease,18 further implicating this inter-
val in the regulation of mucosal inflam-
mation. Two cytokine genes within the
associated region, LIF and OSM, are ex-
cellent positional candidates, as both are
expressed in B cells and may participate
in the regulation of mucosal immunity.
It is not yet known if this locus also influ-
ences aberrant IgA glycosylation. Further
studies, including resequencing of this
locus and evaluation of its effect on se-
rum levels of galactose-deficient IgA1,
will clarify causal variants and their role
in the synthesis of IgA1.
Hit 2: Circulating Antibodies
Directed against
Galactose-Deficient IgA1
Aberrantly glycosylated IgA1 in the
blood of patients with IgAN is found
nearly exclusively within immune com-
plexes bound to IgG or IgA1 antibodies.
We have recently shown that these IgG
antibodies recognize GalNAc-contain-
ing epitopes on the galactose-deficient
hinge regionO-glycans of IgA1, defining
an autoimmune component to IgAN.19
Furthermore, these IgG autoantibodies
exhibit unique features in the comple-
mentarity-determining region 3 (CDR3)
of the variable region of their heavy
chains.13 Specifically, the third position
in CDR3 is typically serine in patients
with IgAN, a feature necessary for effi-
cient binding of the IgG to galactose-de-
ficient IgA1. Importantly, serum levels of
IgG antibodies specific for galactose-
deficient IgA1 correlated with disease
severity, as assessed by the magnitude
of proteinuria. It is not known whether
the CDR3 serine substitution origi-
nates from somatic mutations that
arise during maturation of the anti-
body-producing cells or from inherited
germline mutations. These antibodies
are also present in sera of healthy indi-
viduals, albeit at lower levels. One can
postulate that these antibodies are pro-
duced in response to bacterial or viral
cell-surface GalNAc-containing glyco-
conjugates on commensal or infectious
microorganisms and then cross-react
with galactose-deficient O-linked gly-
cans on IgA1. A predominant IgA1 au-
toantibody response19 directed against
galactose-deficient IgA1 may explain
why some patients have IgA1 as the sole
Ig isotype in the glomeruli. It is to be
noted, however, that the presence of
IgG in the renal biopsy specimens also
correlates with mesangial and endo-
capillary cellularity.20
The strongest signals in the recent
GWAS for IgAN were localized within
the MHC complex (encoding polypep-
tides that present antigens to T
cells),3,21 a region highly associated
with risk for many autoimmune disor-
ders. Based on careful conditional anal-
yses, we identified three independent
susceptibility loci within the MHC com-
plex.3 The strongest genetic effect was
observed for the MHC-II locus contain-
ing the HLA-DQB1, DQA1, and DRB1
genes. This effect appeared to be con-
veyed by a highly protective haplotype
DRB1*1501-DQA1*0102-DQB1*0602.
Specifically, the DQB1*0602 allele re-
duced the odds of disease by over 50%
per copy. This is a relatively common
classical HLA allele, present in 10 to 20%
of Europeans and 2 to 10% of Asians.22
The second independent genetic effect is
from a region encompassing two genes
encoding transporters associated with
antigen processing (TAP1 and TAP2)
and two genes encoding components of
the immunoproteasome (PSMB8 and
PSMB9). These molecules process anti-
gens in the cytosol and transport them
into the endoplasmic reticulum for de-
livery to the cell surface in association
withMHC-I molecules. It is not yet clear
which of these four genes is involved in
the susceptibility to IgAN. Finally, the
third locus of association is on chromo-
some 6p21 and encodes MHC-II mole-
cules DPA1, DPB1, and DPB2, and thus
also relates to the process of antigen
presentation. Taken together, these
new genetic findings strongly implicate
adaptive immunity in the pathogenesis
of IgAN, and define the genetic context
required for the recognition of galac-
tose-deficient IgA1 as an antigen and
for generation of pathogenic anti-
glycan antibodies.
Hit 3: Formation of Pathogenic
IgA1-Containing Immune
Complexes
It is generally agreed that, in IgAN, the
mesangial cells represent the primary
target of pathogenic deposits formed by
circulating immune complexes (Figure 2,
solid lines) or by lanthanic deposits of
aberrantly glycosylated IgA1, followed
by binding of newly generated anti-
glycan antibodies to form immune
complexes in situ (Figure 2, broken
lines).23 The presence of circulating
IgA1-containing immune complexes is
not unique to patients with IgAN. Such
complexes can be detected in persons
without apparent renal disease, includ-
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ing healthy individuals and patients
with Henoch-Schoenlein purpura
without nephritis.19,24,25 The com-
plexes in patients with Henoch-
Schoenlein purpura without nephritis
consist of IgA, but not IgG, and are of
smaller mass than the complexes found
in patients with IgAN. As these persons
do not develop overt renal disease, it
can be assumed that these IgA com-
plexes are not nephritogenic. In con-
trast, patients with Henoch-Schoenlein
purpura with nephritis have larger cir-
culating immune complexes contain-
ing IgA and IgG.24 By analogy with
other human diseases caused by im-
mune complexes, it is likely that, in
IgAN, the molecular proportion of an-
tigens (galactose-deficient IgA1) and
antibodies (IgG or IgA1) determines
the size of the formed immune com-
plexes and, consequently, their rate of
removal from the circulation, as well as
biologic activity. The pathogenic circu-
lating IgA1-IgG immune complexes in
patients with IgAN are relatively large
(800 kD) and thus may be excluded
from entry into the hepatic space of
Disse to reach the asialoglycoprotein
receptor (ASGP-R) on hepatocytes, the
normal catabolic pathway for circula-
tory IgA1. As a result, these immune
complexes enter the renal circulation.
Due to the unique location of the mes-
angium between the fenestrated endo-
thelial lining of the capillaries and the
glomerular basement membrane, the
mesangium is prone to deposition of
immune complexes. While it is not
completely understood what deter-
mines the entry of circulating immune
complexes into the mesangium, the
factors involved likely include the size
of immune complexes, their amount,
and local hemodynamic factors.26 The
biologic activity of large circulating
immune complexes with galactose-
deficient IgA1 increases in IgAN pa-
tients during episodes of macroscopic
hematuria.27 However, it is not known
whether this increase in activity is due to
greater production of galactose-deficient
IgA1, anti-glycan antibodies, or other un-
defined factors influencing the formation
of these complexes and/or their composi-
Podocyte
Cytokines
IgA1 complexes
Proliferation
ECM production
Cytokines
Growth factors
Mesangial cell
Increased circulating
galactose-deficient IgA1 
Production of unique
anti-glycan antibodies 
Hit 2Hit 1
Formation of pathogenic IgA1-containing
circulating immune complexes 
Hit 4
Hit 3
Mesangial deposition and activation of
mesangial cells resulting in glomerular injury 
Figure 2. Proposed pathways involved in the pathogenesis of IgAN: multi-hit mechanism.
Hit 1: Production of galactose-deficient IgA1 by a subpopulation of IgA1-secreting cells. IgA1
production may be affected by the IgAN-associated locus on chromosome 22q12.2.3 Hit 2:
Formation of anti-glycan antibodies with specific characteristics of the variable region of the
heavy chain that recognize galactose-deficient IgA1. Hit 3: Formation of immune complexes
from autoantigen (galactose-deficient IgA1) and O-glycan-specific antibodies. Hits 2 and 3
may be regulated by the threeMHC loci on chromosome 6p21 associated with risk of IgAN.3
Hit 4: Deposition of pathogenic immune complexes in the mesangium, activation of mesangial
cells, and induction of glomerular injury. Hits 3 and 4 may be affected by genotype at the
complement factor H locus on chromosome 1q32 that regulates the alternative complement
cascade.3 The first pathway assumes formation of immune complexes in the circulation and their
subsequent mesangial deposition (solid lines).13,19,55,56 An alternative theory proposes that some
of the aberrantly glycosylated IgA1 molecules are in the mesangium as lanthanic deposits (left
broken line) and are later bound by newly generated anti-glycan antibodies to form immune
complexes in situ (right broken line) that activate mesangial cells.23 ECM, extracellular matrix.
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tion.28,29 MHC risk alleles may participate
in this step by influencing the efficiency of
antigen presentation, recognition, and
processing, and subsequent activation of
autoreactive B cells.
Hit 4: Mesangial Deposition of
IgA1-Containing Immune
Complexes, Cell Activation, and
Initiation of Glomerular Injury
The pathogenetic importance of im-
mune complexes has been shown by in
vitro studies. The glomerular injury of
IgANhistologicallymanifests as prolifer-
ation of mesangial cells and expansion of
extracellular-matrix components. The
detailed mechanisms of activation of
mesangial cells remain to be elucidated.
Nonetheless, cultured human mesangial
cells provide a convenient model for
evaluating the biologic activities of IgA1-
containing complexes. Immune com-
plexes from patients with IgAN contain-
ing galactose-deficient IgA1 bind to the
cells more efficiently than do uncom-
plexed IgA1 or immune complexes from
healthy controls. Complexes with galac-
tose-deficient IgA1 induce cultured hu-
man mesangial cells to proliferate, se-
crete extracellular matrix components,
and release humoral factors such as
TNF, IL-6, and TGF. These factors
can, in turn, alter podocyte gene expres-
sion and glomerular permeability.30,31 In
contrast, uncomplexed galactose-defi-
cient IgA1 or relatively small immune
complexes (800 kD) have no stimula-
tory effect on cellular proliferation.
The cellular receptors on mesangial
cells involved in the binding of IgA1 are
not well characterized. IgA1-containing
immune complexes display a high affin-
ity for the extracellular-matrix compo-
nents fibronectin and type IV collagen in
the mesangium, and preferentially bind
and activate mesangial cells. None of the
well-known IgA receptors (CD89, poly-
meric Ig receptor, ASGP-R) and comple-
ment receptors (CR 1–3) have been con-
firmed on human mesangial cells.32,33
However, transferrin receptor (CD71),
which is expressed on the surface of pro-
liferating human mesangial cells, can
bind polymeric IgA1.34 Moreover, CD71
on human mesangial cells effectively
binds immune complexes containing ga-
lactose-deficient IgA1, leading to en-
hanced expression of CD71.35,36 This
binding creates a positive feedback loop,
causing overexpression of CD71 on pro-
liferating mesangial cells. However, it is
not known whether CD71 is the only re-
ceptor that binds IgA1-containing im-
mune complexes or whether it has a di-
rect pathogenic role in IgAN.
Activation of the complement system
in glomeruli augments the inflammatory
cascade and potentiates tissue injury in
IgAN. The immune complexeswith IgA1
can activate complement via the alterna-
tive or lectin pathway. The pattern of gly-
cosylation of IgA1 and the molecular
mass of IgA1-containing immune com-
plexes are also important factors in the
ability of IgA1 to activate the alternative
complement pathway.37 Accordingly, re-
nal biopsy specimens have usually de-
tectable C3, while the components of the
classical pathway, such as C1q, are typi-
cally absent. Our recent GWAS identi-
fied a major IgAN susceptibility locus
within the complement factor H gene
(CFH) cluster on chromosome 1q32.
Products of CFH and its neighboring
CFHR (CFH-related) genes participate in
the modulation of the alternative path-
way by bindingC3a andC5a convertases.
Mutations in CFH lead to uncontrolled
activation of the alternative pathway and
cause inherited forms of membranopro-
liferative glomerulonephritis type II, a
disease pathologically distinct from
IgAN. However, carriers of a common
deletion encompassing the neighboring
CFHR1 and CFHR3 genes had an ap-
proximately 30%decreased risk of devel-
oping IgAN. The risk was almost 60%
lower in the rare individuals who carry
two copies of this deletion.3 The role of
CFHR1 and CFHR3 proteins in the reg-
ulation of complement cascade is cur-
rently under active investigation. Based
on early experimental data, however,
CFHR1 and CFHR3 compete with CFH
for binding to C3b, the key activator of
the terminal portion of the complement
pathway.38 Therefore, a relative loss of
CFHR1 andCFHR3may enhance the in-
hibitory action of CFH and thus convey
protection against local inflammation.
These mechanistic issues have impor-
tant clinical and therapeutic implications
because subclinical findings consistent
with IgAN are common in the general
population. Necropsy series found glo-
merular IgA deposits in 2% and 4% of
individuals in Singapore and Germany,
respectively.39,40 Even more striking, a
study in Japan showed that 16% of 510
renal allografts at engraftment were af-
fected, of which 19 (3.7%) had a mesan-
gioproliferative nephritis.41 To date, the
glycosylation pattern of this lanthanic
glomerular IgA has not been examined
to determine if it differs from that found
in IgAN patients. Such an analysis would
clarify whether the IgA deposits are clin-
ically silent because they have a different
composition that renders them relatively
inert or because there is an intrinsic hy-
poresponsiveness of the kidney in which
they are deposited.
POTENTIAL NEW DIAGNOSTIC
AND PROGNOSTIC MARKERS
In Blood
Based on the central role of galactose-
deficient IgA1 in the pathogenesis,
Moldoveanu et al.6 investigated the
value of serum levels of this protein as a
diagnostic test. By receiver operating
characteristic (ROC) curve analysis, the
serum level of galactose-deficient IgA1
that provided a 0.77 sensitivity had a
specificity of 0.90 to distinguish IgAN
patients from healthy controls, while a
level with a specificity of 1.00 had a sen-
sitivity of 0.44.6 Other groups have repli-
cated these findings.4,42 Importantly, the
serum level of galactose-deficient IgA1
may be significantly elevated long before
the diagnosis of IgAN (Olson S. et al., un-
published observation).
IgG specific for galactose-deficient
IgA1 represents another potential bio-
marker, as serum levels of this antibody
are significantly elevated in IgAN pa-
tients, and the levels correlate with pro-
teinuria. ROC curve analysis indicates
that when the specificity of the level of
serum IgG antibody directed against ga-
lactose-deficient IgA1 reached 0.95, the
corresponding sensitivity was 0.88.13
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In Urine
Urinaryproteomicsholdspromise fordevel-
opmentofnoninvasivetests forIgAN.Asub-
set of mesangial immune complexes appar-
ently enters the urinary space. Aberrantly
galactosylated IgA1 within immune com-
plexeshasbeen found in theurineofpatients
withIgANbutnotinpatientswithnon-IgAN
proteinuric glomerular diseases.43 It is also
possibletodevelopadiagnostictestwithouta
detailed knowledge of the pathogenesis,
based on analysis of the urinary peptidome.
In a preliminary study, Julian et al.44 found
that analysis of urine samples by capillary
electrophoresis, coupled online with mass
spectrometry, distinguished patients with
primary IgAN from patients with IgA-im-
mune-complexrenaldiseaseduetocirrhosis,
even if clinical proteinuriawas absent.
Genetic
The GWAS of sporadic IgAN identified
five novel genetic variants with relatively
strong protective effects against IgAN.3
While these variants are all common, their
frequencies vary significantly across differ-
ent continental populations and closely
parallel the prevalence rates of IgAN. For
example, African populations, which have
the lowest reported prevalence of IgAN,
carry the most protective alleles, while
Asians, who have the highest reported
prevalence,have significantly fewerprotec-
tive variants. The ROC analysis for a ge-
netic risk score based on these five alleles is
estimated in the range of 0.60 to 0.63, with
the risk score explaining up to 7% of dis-
ease variation amongAsian andCaucasian
populations. Identification of additional
genetic susceptibility loci in follow-up
GWAS studies of Caucasian populations
will likely improve the predictive power of
the genetic risk score. Additionally, a com-
posite risk score based on a combined as-
sessment of circulating, urinary, and ge-
netic disease biomarkers holds promise to
ultimately provide a tool for the noninva-
sive diagnosis of IgAN.
POTENTIAL APPROACHES FOR
DISEASE-SPECIFIC THERAPY
The pathogenesis model (Figure 2) pro-
vides an opportunity to design and test
rational therapies for IgAN (Table 1).
This model predicts that the generation
of nephritogenic immune complexes
composed of galactose-deficient IgA1
and anti-glycan autoantibodies initiates
disease. Therefore, interventions that
can reduce generation of galactose-defi-
cient IgA1 or anti-glycan antibodies, or
block the interaction between these two
components to form nephritogenic im-
mune complexes, may prove effective.
This result can be achieved by enhancing
enzymatic activity of glycosyltransferases
for synthesis of galactose-replete hinge-
regionO-glycans to reduce the availabil-
ity of aberrantly glycosylated IgA1 for
formation of nephritogenic immune
complexes. Alternatively, generation of
non-cross-linking, monovalent reagents
(single-chain antibodies) with high af-
finity for GalNAc on galactose-deficient
IgA1 could theoretically prevent binding
of anti-glycan antibodies. Lastly, block-
ing the antibodies with a glycopeptide
may be another strategy to prevent for-
mation of immune complexes (Table 1).
Similarly, interventions aimed at re-
ducing immune complex deposition and
the downstream inflammatory signals
may prove beneficial. The genetic studies
identify the alternative complement
pathway as a prime candidate for inter-
vention, and predict that targeted deple-
tion of CFHR1 and/or CFHR3 would be
tolerated and prove protective. More-
over, blocking of specific signaling path-
ways induced in mesangial cells by
pathogenic IgA1-containing complexes
can be theoretically accomplished by
protein-kinase inhibitors, a class of drugs
that is frequently used in the treatment of
some types of cancer.
CONCLUSIONS
IgAN is an autoimmune renal disease
arising from consequences of increased
circulating levels of IgA1 with galactose-
deficient hinge-region O-glycans. How-
ever, this glycosylation aberrancy alone is
not sufficient to induce nephritis. For the
clinical manifestation of renal injury,
several additional hits are required, in-
cluding synthesis of circulating antibod-
ies directed against the aberrantly glyco-
sylated O-linked hinge-region glycans to
form immune complexes, accumulation
of the complexes in the mesangium, and
activation ofmesangial cells. Genetic fac-
tors apparently influence the expression
of these hit mechanisms. Elucidation of
the pathogenesis of IgAN provides an
opportunity to develop a disease-specific
therapy that heretofore has beenmissing.
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